Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 70.38% is 14% below its 5-year average of 81.69%, near the low end of its 5-year range (55.65%–111.56%).
As of the fiscal period ended Wednesday, December 31, 2025. 15.72% above its 12-month average of 60.82%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
70.38%
RETURN ON EQUITY (ROE) AVG TTM
60.82%
RETURN ON EQUITY (ROE) AVG 3Y
72.53%
RETURN ON EQUITY (ROE) AVG 5Y
81.69%
RETURN ON EQUITY (ROE) AVG 10Y
-377.44%
RETURN ON EQUITY (ROE) AVG 15Y
61.52%
RETURN ON EQUITY (ROE) AVG 20Y
48.32%
CURRENT VS TTM AVG
+15.72%
CURRENT VS 3Y AVG
-2.96%
CURRENT VS 5Y AVG
-13.84%
CURRENT VS 10Y AVG
+118.65%
CURRENT VS 15Y AVG
+14.39%
CURRENT VS 20Y AVG
+45.67%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+546.28%
vs the sector median at left
IDEXX Laboratories, Inc.
Market Cap
$42.94B
Return on Equity (ROE)
70.38%
TTM Avg
60.82%
3Y Avg
72.53%
5Y Avg
81.69%
Market Cap
$39.14B
Return on Equity (ROE)
19.85%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$46.74B
Return on Equity (ROE)
6.08%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$47.58B
Return on Equity (ROE)
10.58%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
Market Cap
$36.28B
Return on Equity (ROE)
53.68%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$34.72B
Return on Equity (ROE)
22.26%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$32.77B
Return on Equity (ROE)
8.55%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$53.41B
Return on Equity (ROE)
-56.13%
TTM Avg
-41.33%
3Y Avg
9.62%
5Y Avg
-22.30%
Market Cap
$31.59B
Return on Equity (ROE)
81.75%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $42.94B | 70.38% | 60.82% | 72.53% | 81.69% |
| Agilent Technologies, Inc. (A)vs › | $39.14B | 19.85% | 20.59% | 21.51% | 20.54% |
| Humana Inc. (HUM)vs › | $46.74B | 6.08% | 7.05% | 11.93% | 15.09% |
| Edwards Lifesciences Corporation (EW)vs › | $47.58B | 10.58% | 26.07% | 24.86% | 23.86% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $36.28B | 53.68% | -187.43% | 134.89% | 51.69% |
| IQVIA Holdings Inc. (IQV)vs › | $34.72B | 22.26% | 21.77% | 21.17% | 17.55% |
| Medline Inc. (MDLN)vs › | $32.77B | 8.55% | 9.02% | 4.86% | 4.86% |
| Cardinal Health, Inc. (CAH)vs › | $53.41B | -56.13% | -41.33% | 9.62% | -22.30% |
| Zoetis Inc. (ZTS)vs › | $31.59B | 81.75% | 66.19% | 56.82% | 52.60% |
| Centene Corp. (CNC)vs › | $31.31B | -30.07% | -10.46% | -1.37% | 1.10% |
ROE
70.4%
ROA
32.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 65.99% |
| 2024-12-31 | 55.65% |
| 2023-12-31 | 56.92% |
| 2022-12-31 | 111.56% |
| 2021-12-31 | 107.95% |
| 2020-12-31 | 92.04% |
| 2019-12-31 | 241.01% |
| 2018-12-31 | -3963.32% |
| 2017-12-31 | -486.35% |
| 2016-12-31 | -204.93% |
| 2015-12-31 | -228.32% |
| 2014-12-31 | 154.79% |
| 2013-12-31 | 36.24% |
| 2012-12-31 | 28.02% |
| 2011-12-31 | 29.98% |
| 2010-12-31 | 24.60% |
| 2009-12-31 | 23.75% |
| 2008-12-31 | 26.51% |
| 2007-12-31 | 21.45% |
| 2006-12-31 | 22.86% |
| 2005-12-31 | 21.21% |
| 2004-12-31 | 19.70% |
| 2003-12-31 | 13.81% |
| 2002-12-31 | 13.31% |
| 2001-12-31 | 12.47% |
| 2000-12-31 | 14.00% |
| 1999-12-31 | 11.47% |
| 1998-12-31 | -4.94% |
| 1997-12-31 | -6.97% |
| 1996-12-31 | 10.10% |
